MyCartis announces launch of digital multiplex biomarker analysis platform

MyCartis today announced the launch of Evalution™, a multiplex biomarker analysis platform for the life sciences research market.

Evalution™ is MyCartis' digital multiplex analysis platform tailored to clinical research and pharmaceutical markets and designed to analyze a broad range of protein and nucleic acid-based biomarkers, delivering high quality data and rapid results. Evalution™ provides an integrated reaction and detection environment and simultaneous analysis of large numbers of analytes per assay.

Biocartis' Swiss business unit Evalution™ and Belgian-based Pronota NV have recently joined forces in MyCartis NV. The combination of the Evalution™ platform as designed by Biocartis, and Pronota's portfolio of validated biomarkers will deliver state-of-the-art solutions for a range of diseases in the fields of cardiovascular and women's health.

"We believe that every individual has the right to good health. But we know that the current health model of 'one size fits all' is unsustainable", said Paul Ladestein, CEO of MyCartis. "By developing biomarker analysis solutions at the forefront of innovation we want to improve healthcare worldwide. Our next generation multiplexing platform Evalution™ will support researchers to better understand the role of biomarkers in early disease and risk diagnosis and patient management. Evalution™ can analyse an individual's protein and molecular profile in a single assay plate".

Besides serving the research community, MyCartis also engages in licensing opportunities with companies aiming to develop their own commercial applications on the Evalution™ platform. Furthermore, MyCartis also develops and validates novel applications with simpler assay formats and unique biomarkers for a range of diseases.

The launch of Evalution™ was announced at the HUPO event in Madrid. MyCartis also launches a new brand identity, including a new website and a blog, in which key opinion leaders and experts in biomarker research and personalized healthcare are interviewed.